Mr. David Walsh:

I will take the first question. On vulnerable patients, there is a considerable amount of correspondence from various senior clinical people across the system to Dr. Henry in regard to the issue. It is important to understand how the current schedule came about, which, as I understand it, was on the basis of a recommendation from the national immunisation advisory committee, NIAC, to the Department and onwards to Government. This is where the current scheduling came from. With regard to when the particular cohort mentioned by the Deputy will be reached, as I said earlier, if we can capture the majority of people through GPs or pharmacies, that is the way to go, but we need to make sure people do not fall through the cracks. I recognise that there are a significant number of groups that may not agree with the current scheduling and have written to us in that regard. I am not aware of any process of review or anything like that.

We will continue to follow the current schedule and maximise the number of vaccines we have to deploy in order to get to those groups as quickly as possible, recognising that where there are exceptional circumstances we will have to put in exceptional measures to make sure that those people can get their vaccination.

The Johnson & Johnson question might pass on to Professor MacCraith.